Related Experiment Video
Updated: Aug 11, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Selegiline hydrochloride and cognition
1Department of Neurology, Middlesex Hospital, London, UK.
Abstract:
Selegiline HCl, 10 mg per day has been reported to improve attention and episodic memory in Parkinson's disease and early Alzheimer's disease. Selegiline also improves motor reaction times in Parkinson's and subjective feelings of increased vitality, euphoria and energy. At doses of between 10 and 40 mg a day it has also been shown to improve depression particularly when psychomotor retardation is prominent and anxiety minimal.
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antidepressant Drugs: MAOIs and Other Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Dementia l: Introduction

